Key Details
The draft amendments seek to modernise India’s pharmaceutical import framework by making research imports easier and medicine supply chains more efficient, while preserving stricter oversight for sensitive drug categories.
Reform Area | Proposed Change | Policy Objective |
|---|---|---|
Imports for testing and analysis | Small quantities of drugs may be imported through prior intimation and acknowledgement instead of the existing permission process | Reduce delays for pharmaceutical R&D and analytical testing |
Risk-based safeguards | Simplified procedure will not apply to sex hormones, cytotoxic drugs, beta-lactam drugs, biologics containing live microorganisms, or narcotic and psychotropic substances | Maintain tighter oversight over higher-risk products |
Shelf-life norms | Most imported medicines will require a minimum residual shelf life of 12 months instead of the current 60% requirement | Improve inventory planning and medicine availability |
Exemptions | Biological products and radiopharmaceuticals will continue to require more than 60% residual shelf life | Protect quality and stability of specialised medicines |
Consultation | Draft amendments released for stakeholder comments | Encourage consultative regulatory reform |
Summary
Two Import Reforms Target Different Bottlenecks
The Ministry of Health and Family Welfare has released two draft amendments to the Drugs Rules, 1945 that seek to simplify India’s pharmaceutical import framework. While one proposal focuses on making it easier to import small quantities of drugs for research and testing, the other aims to rationalise shelf-life requirements for imported medicines. Together, the reforms reflect a shift towards risk-based regulation that reduces unnecessary compliance while retaining safeguards where public-health risks are higher.
Simplifying Imports for Research and Product Development
The first proposal replaces the existing permission-based process for importing small quantities of drugs for examination, testing and analysis with an acknowledgement-based system. Pharmaceutical companies, startups, research laboratories and testing facilities would be able to proceed with imports after submitting prior intimation and receiving an acknowledgement, reducing procedural delays for analytical and non-clinical research.
The simplified route will not apply to sensitive categories such as sex hormones, cytotoxic drugs, beta-lactam drugs, biologics containing live microorganisms, and narcotic and psychotropic substances, which will continue to require prior licensing.
Making Medicine Supply Chains More Efficient
The second proposal seeks to amend Rule 31 by replacing the current requirement that imported medicines must have more than 60% residual shelf life with a simpler benchmark of at least 12 months of residual shelf life at the time of import.
The change is expected to make inventory management more predictable and reduce avoidable restrictions on imported medicines. However, biological products and radiopharmaceuticals will continue to follow the existing 60% requirement because of their specialised handling and stability considerations.
A Move Towards Smarter Pharmaceutical Regulation
Taken together, the draft amendments illustrate a broader regulatory approach that combines Ease of Doing Businesswith public-health safeguards. By easing procedures for low-risk activities while maintaining stricter controls over sensitive medicines, the Government seeks to create a pharmaceutical regulatory system that is more research-friendly, supply-chain efficient and proportionate to risk.
Policy Relevance
Supports Ease of Doing Business by simplifying import procedures for pharmaceutical research and analytical testing.
Encourages pharmaceutical innovation by reducing procedural delays for startups, research laboratories and manufacturers.
Introduces a more risk-based regulatory framework, easing compliance for low-risk activities while retaining stricter controls over sensitive medicines.
Improves medicine availability by making residual shelf-life requirements more practical for imported drugs.
Maintains stronger safeguards for biological products, radio pharmaceuticals and other higher-risk drug categories.
Continues India’s broader shift towards simpler, consultative and outcome-oriented pharmaceutical regulation.
Relevant Question for Policy Stakeholders: What safeguards will be needed to ensure that simplified import procedures for research remain confined to genuine analytical and non-clinical testing rather than becoming an alternative commercial import route?
Follow the Full Notifications Here:
https://egazette.gov.in/WriteReadData/2026/273833.pdf
Draft Amendment to Rationalise Residual Shelf-Life Requirement for Imported Drugs